European journal of cancer (Oxford, England : 1990) · 2025
Plasma Epstein-Barr virus DNA for disease surveillance in endemic nasopharyngeal carcinoma: Analysis of a real-world database.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Neo Jialing, Ong Enya H W, Zhang Xin, Chow Wen Min, Wee Joseph T S, Fong Kam Weng, Soong Yoke Lim, Tan Terence W K, Liu Jianjun, Loh Kwok Seng, Tay Joshua K, Ang Mei Kim, Tan Sze Huey, Lim Darren W T, Chua Melvin L K
Аннотация
AIM: Plasma Epstein-Barr virus (EBV) DNA is an archetypal biomarker for endemic nasopharyngeal carcinoma (NPC) employed for disease surveillance and early detection of recurrences. However, its accuracy is unknown. We utilised a single institution dataset with homogeneous surveillance procedures and routine EBV DNA testing using a harmonised assay to investigate its accuracy for recurrence detection.
METHODS: We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised BamHI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals - windows 1-4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation.
RESULTS: Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (< 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6-99.3 %). PPVs were modest, highest at window 1 (range: 26.3-34.3 %) compared with the other 3 windows (range: 2.6-10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4-100 % at window 1 for ≥ 500 copies/mL versus 16.9-23.1 % for < 500 copies/mL, which corresponded to median time of recurrence onset (0.8 vs 4.8 months, respectively).
CONCLUSIONS: Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.
METHODS: We utilised a cohort of patients with histologically-confirmed, non-metastatic NPC treated from February, 2017 to July, 2023. All patients had ≥ 1 EBV DNA test using the harmonised BamHI-W polymerase chain reaction-based assay within 3 years post-radiotherapy (RT). We analysed the negative (NPV) and positive predictive values (PPV) for recurrence over a 1-year window (at 3-monthly intervals - windows 1-4) for each test performed. Recurrence was ascertained by radiological imaging and/or histopathological confirmation.
RESULTS: Of 1746 EBV DNA readings from 393 patients diagnosed between January, 2017 to May, 2023, 1385 (79.3 %), 294 (16.8 %), and 67 (3.9 %) were recorded as negative, low (< 500 copies/mL), and high EBV DNA (≥ 500 copies/mL), respectively. NPVs of the assay were high (range: 97.6-99.3 %). PPVs were modest, highest at window 1 (range: 26.3-34.3 %) compared with the other 3 windows (range: 2.6-10.5 %). Sensitivity analyses revealed that PPVs were threshold-dependent; 71.4-100 % at window 1 for ≥ 500 copies/mL versus 16.9-23.1 % for < 500 copies/mL, which corresponded to median time of recurrence onset (0.8 vs 4.8 months, respectively).
CONCLUSIONS: Negative EBV DNA test results have high NPVs, suggesting that patients may be routinely surveyed, while a positive result of ≥ 500 copies/mL indicates high recurrence risk.